JPMorgan analyst Andrea Teixeira raised the firm’s price target on Colgate-Palmolive to $90 from $88 and keeps an Overweight rating on the shares. The household and personal care Q4 earnings season will likely be worse sequentially as companies lap the benefit of pricing and, while volume comps are getting easier, demand has been softer for most, the analyst tells investors in a research note. That said, the firm believes that as the December fiscal year companies guide into 2024, it will look like a more normalized year for the most part, coming back to the pre-pandemic cadence of organic sales growth of 3%-4% with more balanced between volume and pricing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CL:
- Colgate-Palmolive price target raised to $82 from $75 at Barclays
- Colgate-Palmolive price target raised to $88 from $87 at Deutsche Bank
- CL, MDLZ, CELH: Which is the Best Consumer Defensive Stock for 2024?
- Colgate-Palmolive (NYSE:CL): A “Strong Buy” Dividend Aristocrat Stock
- Colgate-Palmolive just upgraded at BofA, here’s why